Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock. SGMO has been the topic of several other research reports. Jefferies Financial Group […]